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Abstract
Natural products are characterized by high chemical diversity and biochemical specificity; 
therefore, they are appealing as lead compounds for drug discovery. Given the importance of 
angiogenesis to many pathologies, numerous natural products have been explored as potential 
anti-angiogenic drugs. Ocular angiogenesis underlies blinding eye diseases such as retinopathy of 
prematurity (ROP) in children, proliferative diabetic retinopathy (DR) in adults of working age, 
and age-related macular degeneration (AMD) in the elderly. Despite the presence of effective 
therapy in many cases, these diseases are still a significant health burden. Anti-VEGF biologics 
are the standard of care, but may cause ocular or systemic side effects after intraocular 
administration and patients may be refractory. Many anti-angiogenic compounds inhibit tumor 
growth and metastasis alone or in combination therapy, but a more select subset of them has been 
tested in the context of ocular neovascular diseases. Here, we review the promise of natural 
products as anti-angiogenic agents, with a specific focus on retinal and choroidal 
neovascularization. The multifunctional curcumin and the chalcone isoliquiritigenin have 
demonstrated promising anti-angiogenic effects in mouse models of DR and choroidal 
neovascularization (CNV) respectively. The homoisoflavanone cremastranone and the flavonoid 
deguelin have been shown to inhibit ocular neovascularization in more than one disease model. 
The isoflavone genistein and the flavone apigenin on the other hand are showing potential in the 
prevention of retinal and choroidal angiogenesis with long-term administration. Many other 
products with antiangiogenic potential in vitro such as the lactone withaferin A, the flavonol 
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quercetin, and the stilbenoid combretastatin A4 are awaiting investigation in different ocular 
disease relevant animal models. These natural products may serve as lead compounds for the 
design of more specific, efficacious, and affordable drugs with minimal side effects.
Keywords
angiogenesis; natural compounds; blinding diseases; small molecules; choroidal 
neovascularization; retinal neovascularization; polyphenols
1. Introduction
The medicinal use of natural compounds derived from plants, animals and microorganisms 
was introduced in ancient medicine thousands of years ago (Ji et al., 2009). Natural products 
served as the sole pharmacological source for the treatment of diseases for most of human 
history, where some herbs were chewed to relieve pain, and others were applied topically on 
wounds to improve healing. Screening natural products to provide novel human therapeutics 
was maximized by the Western pharmaceutical industry resulting in a broad spectrum of 
pharmaceuticals from non-synthetic molecules (Newman et al., 2003). In the 19th century, 
the development of analytical and structural chemistry provided the tools to purify different 
compounds from natural sources and to determine their structures, which in turn, provided 
information about their possible molecular targets in the human body (Ji et al., 2009). In the 
20th century, most approved drugs were natural products or analogues derived from them. 
Natural source-derived antibiotics such as the penicillins, immunosuppressants for organ 
transplants such as cyclosporine, and anticancer drugs such as taxols revolutionized 
medicine and improved quality of life (Li and Vederas, 2009). The functions and structures 
of natural products and their molecular targets are believed to have evolved to interact with 
one another (Schmidt et al., 2007), suggesting that natural products might serve as optimal 
small molecule ligands for some human targets.
Despite these advantages, a decline in natural products-based drug discovery has been 
experienced in the past decades with the advent of molecular biology and rational, structure-
based design that made it possible to design synthetic chemicals to target specific proteins. 
However, the past few years have witnessed a resurgence of interest in the use of natural 
compounds as a basis for drug development, with several promising compounds having 
undergone clinical evaluation for the treatment of varied conditions such as neoplastic, 
immunological, and inflammatory diseases (Mishra and Tiwari, 2011).
Interest in natural products will continue for many reasons: they are a matchless source of 
novel drug leads and inspiration for the synthesis of synthetic or semi-synthetic molecules 
(Mishra and Tiwari, 2011), they can work synergistically to potentiate the activity of other 
drugs and overcome drug resistance (Schmidt et al., 2007), and they can offer powerful 
leads with favorable absorption, distribution, metabolism, excretion, and toxicity (ADMET) 
characteristics (Corson and Crews, 2007). Advances in separation and structure 
determination technologies, along with the ability to modulate biological activity through 
structural modifications, have made a wide variety of natural products and derivatives 
readily available (Koehn and Carter, 2005).
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Numerous natural compounds have been tested as inhibitors of uncontrolled angiogenesis in 
various pathological conditions, such as cancer and inflammation, and also in blinding eye 
diseases. The concept of angiogenesis as an important therapeutic target was initially 
introduced due to its involvement in tumor growth and metastasis (Folkman, 1995). 
Pathological ocular angiogenesis (neovascularization) however, underlies several non-
neoplastic ocular disorders that can cause blindness. Ocular neovascularization has a 
significant contribution to ROP, DR, AMD, neovascular glaucoma, retinal vein occlusion, as 
well as other ocular diseases (Zhang and Ma, 2007). In this review, we will discuss 
promising natural compounds that demonstrate inhibition of ocular angiogenesis. We will 
explore their potential in the prevention/treatment of ocular neovascular diseases either 
alone or in combination with the standard therapies.
2. Angiogenesis in ocular health and disease
Angiogenesis is a highly regulated process that involves the formation of new blood vessels 
from existing ones, which is kept under the control of positive (angiogenic) and negative 
(anti-angiogenic) endogenous factors (Carmeliet and Jain, 2011). This process is clearly 
different from vasculogenesis, the de novo synthesis of blood vessels from endothelial 
progenitor cells. Angiogenesis not only requires endothelial cell migration and proliferation, 
but also vessel maturation, vessel remodeling, and degradation of extracellular matrix. 
Angiogenesis is the major mechanism of vascular growth during embryonic development 
and wound healing. Under normal conditions, endothelial cells are quiescent without 
significant proliferation, due to a balance in the expression level and function of angiogenic 
factors such as vascular endothelial growth factor (VEGF) and angiostatic factors such as 
pigment epithelium derived factor (PEDF) (Folkman and Ingber, 1992).
During rapid uncontrolled ocular angiogenesis, fragile and leaky vasculature is formed. This 
leads to hemorrhage and accumulation of fluids and protein exudates in ocular cavities, 
causing reduction in the transparency of the cornea and impairment of the structure and 
function of retinal neurons resulting in vision loss. These vessels may induce the formation 
of fibrous scarring, causing irreversible damage to retinal function that can eventually result 
in blindness if left untreated (Zhang and Ma, 2007).
3. Existing anti-angiogenic drug therapies
Therapeutic approaches currently available for ocular neovascular diseases aim to seal off 
the leaky vasculature using laser photocoagulation and/or photodynamic therapy as well as 
inhibit new vessel formation (Dorrell et al., 2007). The major angiogenic factor in 
neovascularization is VEGF. Therefore, several anti-VEGF drugs have been recently used 
such as pegaptanib (Macugen®, Valeant), bevacizumab (Avastin®, Genentech), 
ranibizumab (Lucentis®, Genentech) and aflibercept (Eylea®, Regeneron). Pegaptanib is an 
aptamer engineered to bind specifically to VEGF165, the isoform primarily responsible for 
pathological ocular angiogenesis (Ng et al., 2006). Bevacizumab is a humanized monoclonal 
antibody to VEGF inhibiting VEGF-receptor interaction (Gunther and Altaweel, 2009). 
Ranibizumab is a recombinant humanized fraction of anti-VEGF antibody that binds to all 
VEGF isoforms (Rosenfeld et al., 2006). Aflibercept, known as VEGF Trap, is a fusion 
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protein that consists of VEGF receptor-binding sequences fused to a segment of a human 
antibody backbone (Stewart, 2012a).
These drugs all act by targeting the VEGF signaling pathway at the level of ligand-receptor 
interaction. They have been shown to be successful in many AMD patients. Meanwhile, 
they are still under investigation for their potential therapeutic effect on ROP and DR 
(Andreoli and Miller, 2007). However, a significant number of AMD patients remain 
unresponsive (Lux et al., 2007). As biologics, these drugs have an unfavorable cost to 
benefit ratio (Mitchell et al., 2011). Moreover, since VEGF signaling is also required for the 
survival of quiescent endothelial cells and glial cells that nourish endothelial cells in almost 
all the tissues of the body, these drugs can cause significant systemic side effects such as 
myocardial infarction, stroke, delayed wound healing and non-ocular hemorrhage even 
when the drugs are administered intravitreously (Stewart, 2012b). Additionally, several 
ocular side effects can be associated with intravitreous injections of anti-VEGF drugs, such 
as intraocular inflammation, ocular hemorrhage, and retinal detachment (Falavarjani and 
Nguyen, 2013). Therefore, there is a strong need to develop new, affordable drugs 
specifically targeted for ocular angiogenesis with minimal side effects to complement and 
perhaps combine with existing therapies.
4. Anti-angiogenic natural products and ocular neovascular diseases
A select subset of natural compounds, spanning a variety of compound classes, have been 
tested for their effects in ocular neovascular diseases specifically, and some have very 
promising activity (Table 1). Polyphenols are the most abundant secondary metabolites, 
constituting the active substances in many medicinal plants. They have long been recognized 
for their antioxidant properties (Manach et al., 2004). Therefore, they have been tested for 
their potential therapeutic effects in many diseases such as cancer and inflammatory and 
cardiovascular diseases. Polyphenols are loosely defined as having several hydroxyl groups 
on aromatic rings. They are divided into classes such as phenolic acids, flavonoids, 
stilbenoids and lignans, according to the number of phenolic groups and the structures that 
connect these rings to one another (Manach et al., 2004). The flavonoids are the most 
common class of polyphenolic compounds that are found ubiquitously in plants. They share 
a common structure of two aromatic rings that are connected together by three carbon atoms 
that form an oxygenated heterocycle (Manach et al., 2004). They are divided into subclasses 
according to the substitutions on the heterocycle and the position and length of the linker 
between the cyclic moieties, and include flavonols (e.g., quercetin), flavones (e.g., luteolin 
and apigenin), isoflavones (e.g., genistein), flavanones (e.g., hesperetin) and 
homoisoflavanones (e.g., cremastranone) (Figure 1). Many flavonoids have been studied for 
their beneficial roles in ocular diseases (Majumdar and Srirangam, 2010).
5. Natural products in ocular neovascularization models
5.1. In vitro models
In vitro models for angiogenesis utilize cultured endothelial cells to test the effects of the 
compounds on cell proliferation, migration and tube formation. Endothelial cell proliferation 
can be investigated by multiple assays, such as MTT (Denizot and Lang, 1986) or EdU 
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incorporation assays (Buck et al., 2008). Migration of endothelial cells can be evaluated in 
vitro by techniques such as the scratch wound migration assay (Liang et al., 2007). Tube 
formation is one of the most common tests for angiogenesis, which measures the ability of 
endothelial cells to form three-dimensional structures (tubes) (Madri et al., 1988).
Human umbilical vein endothelial cells (HUVECs) and bovine aortic endothelial cells 
(BAECs) are established cell systems. These in vitro systems provide a rapid, practical and 
reproducible way for screening of large numbers of compounds. However, for screening of 
compounds specifically for ocular angiogenesis, it is important to use more relevant, tissue 
specific endothelial cells; human retinal microvascular endothelial cells (HRECs) are a 
popular choice in this case, and are commercially available. Nearly all the natural 
compounds discussed below were effective in angiogenesis inhibition in vitro. The majority 
of them were tested in HUVECs, a model endothelial cell line, but not from the same 
vascular bed as those endothelial cells implicated in ocular diseases. Withaferin A (14) was 
the most potent in inhibiting proliferation with GI50 12 nM (Mohan et al., 2004). Genistein 
(3) and quercetin (6) showed equal potencies in inhibiting BAEC proliferation at 20 µM 
concentration (Jackson and Venema, 2006; Koroma and de Juan, 1994). Luteolin (1), 
hesperetin (4), cremastranone (5) and synthetic derivatives, curcumin (9), and decursin (13) 
were tested in the most disease-relevant cells, HRECs. SH-11037, a synthetic derivative of 
cremastranone (5) that we developed, showed the highest potency in these cells, compared 
to other compounds, with GI50 150 nM, and with 10-fold selectivity over HUVECs 
(Basavarajappa et al., 2014).
5.2. In vivo models
5.2.1. Proliferative DR—In healthy adults, the ocular vasculature is mainly quiescent 
under the control of endogenous anti-angiogenic factors such as PEDF and angiostatin (Qazi 
et al., 2009). The abnormal growth of new blood vessels, such as retinal neovascularization, 
interferes with normal functions in regulating light transmission. Numerous clinical and 
experimental studies have identified ischemia as one of the major causes of retinal 
neovascularization (Ashton et al., 1954). One of the most common forms of retinal 
neovascularization is proliferative DR, a common cause of blindness in patients between 25 
and 65 years old. Persistent hyperglycemia, high blood pressure and hypoxia in diabetic 
patients contribute to retinopathy and damage to retinal capillaries. This is followed by the 
proliferative stage, where new, aberrant blood vessels grow along the retina and into the 
vitreous; this is sometimes exacerbated by the formation of fibrovascular scarring and retinal 
detachment (Grossniklaus et al., 2010). With an increasing diabetic population in the United 
States, approximately 700,000 Americans have diabetic retinopathy, with an annual 
incidence of 65,000 new cases (Zhang et al., 2010).
Currently, there is no perfect model for proliferative DR; the most commonly used animal 
model is induced by intraperitoneal (i.p.) administration of streptozotocin (STZ) in mice and 
rats (Jo et al., 2013). The hyperglycemic action of STZ induces diabetes and the 
development of retinopathy later with the disease progression. Many natural compounds 
including genistein (3), hesperetin (4), curcumin (9), resveratrol (10), and decursin (13) 
demonstrated potential in ameliorating retinopathy in the STZ model after oral 
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administration. Due to the lack of proliferative DR in this model (Lai and Lo, 2013), 
retinopathy was defined as increased vascular leakage that was ameliorated by genistein (3) 
and hesperetin (4). In the case of other compounds, retinopathy was evaluated by the extent 
of diabetes-induced metabolic abnormalities that are known to be important in development 
of DR. Effects seen were due to inhibiting retinal oxidative stress and/or increasing 
antioxidant defense systems as seen with hesperetin (4), and curcumin (9) (Kowluru and 
Kanwar, 2007; Kumar et al., 2013), or due to suppressing the production of pro-
inflammatory mediators and growth factors as in the case of resveratrol (10), and decursin 
(13) (Soufi et al., 2012; Yang et al., 2013). Meanwhile, combretastatin A4 (12) failed to 
show an effect in long-term galactose fed dogs, a preclinical model for DR where 
neovascularization slowly develops over a period of months to years as in clinical cases 
(Kador et al., 2007). To our knowledge, no other negative ocular angiogenesis studies on 
any compound discussed here have been presented.
5.2.2. ROP—ROP is a form of retinal neovascularization that is developmental in origin 
(Smith, 2002). Retinal vascularization starts at approximately the 16th week of gestation and 
completes by full-term pregnancy (i.e. 40th week of gestation). Hence, premature babies 
have incomplete retinal vasculature and upon exposure to oxygen therapy (hyperoxia) 
during neonatal intensive care, this incomplete retinal vasculature decays. This condition is 
more pronounced in premature babies with birth weight less than 1250 g (Sapieha et al., 
2010). During this hyperoxia, the expression of hypoxia-driven angiogenic factors is 
downregulated, resulting in a retardation of existing retinal blood growth, which increases 
the metabolic requirement of the retina on return to normoxia, stimulating abnormal blood 
vessel formation. ROP severity ranges from mild with no visual defects to aggressive 
neovascularization causing blindness and retinal detachment that is responsible for 6–18% 
of total childhood blindness cases (Coats, 2005). Vision loss in about 1300 children every 
year has been estimated in the United States alone, with many more cases worldwide, 
especially as survival of premature infants increases in developing countries (Javitt et al., 
1993).
Oxygen-induced retinopathy (OIR) is the major model in use for study and evaluation of 
pathological angiogenesis resulting from ischemia such as retinal neovascularization (Smith 
et al., 1994). In this model, early postnatal animals are exposed to hyperoxia during early 
retinal development and remain in the oxygen chamber for 5 days (P7). After their return to 
room air, neovascularization is noticed within about 5 days (P12). The OIR model mimics 
the pathological characteristics of ROP, with a consistent and reproducible angiogenic 
response; therefore, it has become important for studying the disease mechanisms and 
investigating potential treatments for ROP (Smith et al., 1994). Several natural compounds 
demonstrated anti-angiogenic effects in the OIR model with different potencies suggesting 
their potential in the treatment of ROP. Luteolin (1) and deguelin (8) showed equal 
potencies in suppressing retinal neovascularization after intravitreal injection of 0.1 µM 
compound concentration on P14 (Kim et al., 2008c; Park et al., 2012). Meanwhile, genistein 
(3), resveratrol (10), honokiol (11), and combretastatin A4 (12) were effective after multiple 
systemic intraperitoneal injections (Griggs et al., 2002; Kim and Suh, 2010; Vavilala et al., 
2013; Wang et al., 2005).
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5.2.3. AMD—The choroid, a highly vascularized compartment of the eye responsible for 
delivering nutrients and oxygen to the photoreceptors, is also susceptible to 
neovascularization. In this case, aberrant vasculature can originate in the choroid and grow 
through a break in Bruch's membrane to the subretinal space, precipitating vision loss. This 
break may be secondary to trauma, a degenerative process, and/or tissue inflammation 
(Grossniklaus and Green, 2004). Choroidal neovascularization (CNV) is seen in “wet” 
AMD, one of the major causes of vision loss among people over 55 years old (Jager et al., 
2008). Wet AMD accounts for about 90% of AMD-related blindness with about 200,000 
new cases diagnosed every year in the United States (Congdon et al., 2004). CNV can lead 
to edema and damage of the macula, causing vision loss in the center of the retina.
Laser-induced CNV, in mouse or rat, is the most popular model that has been used to study 
the role of tissue factors in CNV formation, as well as the evaluation of potential 
pharmacologic therapies for CNV (Dobi et al., 1989). In this model, laser photocoagulation 
spots are introduced into the otherwise normal choroid through the dilated mouse/rat pupil. 
These burns create breaks in Bruch's membrane, which lead to the growth of new blood 
vessels from the choroid into the subretinal space, recapitulating the main pathological 
features in wet AMD (Tobe et al., 1998). Despite the artificial nature of the laser-induced 
CNV model, and the fact that mice and rats do not have a macula, it is currently a standard 
animal model in AMD research (Lambert et al., 2013). Several natural compounds such as 
apigenin (2), genistein (3), cremastranone (5), quercetin (6), isoliquiritigenin (7), deguelin 
(8), and combretastatin A4 (12) showed a significant reduction in neovascularization after 
laser photocoagulation. Deguelin (8) was the most potent in inhibiting neovascularization 
after intravitreal injection at 0.1 µM concentration (Kim et al., 2008b). Cremastranone (5) 
was of moderate potency at 1 µM concentration (Kim et al., 2008a), compared to 
isoliquiritigenin (7), which was effective in the 10-200 µM range (Jhanji et al., 2011). 
Apigenin (2) and combretastatin A4 (12) suppressed CNV formation when administered 
systemically (Nambu et al., 2003; Zou and Chiou, 2006). Genistein (3) showed partial 
inhibition of CNV formation, compared to specific inhibitors of VEGF/PEDF receptor 
kinases, when given systemically (Kwak et al., 2000). While systemic drug administration is 
favored over the intravitreal route, it is influenced by different challenges, such as the blood-
retinal barrier, that will control the effectiveness of the drug reaching the eye (Macha and 
Mitra, 2003). On the other hand, the intravitreal route is more effective in delivering 
maximum concentration of the drug to the eye with minimal systemic side effects; therefore, 
it is the most commonly used for treatments of ocular neovascular diseases.
6. Mechanisms of angiogenesis inhibition by natural products
Identification of the mechanisms of action of anti-angiogenic compounds is a crucial step for 
them to proceed to clinical trials. Most of the natural compounds under investigation have 
been tested for their effect on known angiogenic pathways (Figure 2). However, elucidating 
novel pathways for angiogenesis inhibition is vital to overcome the resistance that might 
emerge with long-term administration of angiogenic inhibitors (Kerbel and Folkman, 2002).
Apart from VEGF, the most dominant angiogenic factor in neovascularization, other growth 
factors such as fibroblast growth factor (FGF) and angiogenin have also been shown to 
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promote angiogenesis (Qazi et al., 2009). On the other hand, there are several endogenous 
anti-angiogenic factors such as PEDF, thrombospondin-1 (TSO-1), and angiostatin that are 
required to maintain homeostasis of angiogenesis (Nyberg et al., 2005). The balance 
between endogenous pro- and anti-angiogenic factors tightly regulates homeostasis of ocular 
vasculature. When this balance is disturbed, formation of new blood vessels occurs, which is 
implicated in the diseases discussed above. Under certain conditions, the production of 
angiogenic stimuli causes endothelial cells to secrete proteases such as matrix 
metalloproteases (MMP) and collagenases, which leads to degradation and remodeling of 
the extracellular matrix (ECM). Apigenin (2) and isoliquiritigenin (7) were shown to inhibit 
HUVEC migration and tube formation by downregulating MMPs (Kang et al., 2010; Kim, 
2003).
Proangiogenic stimuli such as VEGF and FGF bind to cell surface receptors and activate 
downstream signaling cascades to promote migration and proliferation of endothelial cells 
through the newly formed gaps generating new capillaries through which blood begins to 
flow. Interference with angiogenesis at the receptor level has been demonstrated by natural 
compounds such as luteolin (1) and honokiol (11), which inhibited VEGFR2 
autophosphorylation and activation in HUVECs (Bagli et al., 2004; Bai et al., 2003), and 
decursin (13) in HRECs (Yang et al., 2013). Other compounds inhibited the activation of 
downstream signaling pathways of growth factors such as luteolin (1) which inhibited 
VEGF-induced PI3K/Akt activation in HUVECs (Bagli et al., 2004), and curcumin (9) 
which blocked VEGF-induced PKCβII translocation in HRECs (Figure 2) (Premanand et al., 
2006). Cremastranone (5) inhibited FGF signaling in HUVECs (Shim et al., 2004). Growth 
factors also increase vascular permeability through stimulation of nitric oxide (NO) 
synthesis and release from endothelial cells, a step that was inhibited by quercetin (6) and 
resveratrol (10) (Jackson and Venema, 2006; Kim and Suh, 2010).
Tumor necrosis factor-α (TNF-κ) is a very potent angiogenic stimulator that binds to TNF 
receptors and activates nuclear factor-kappa B (NF-kB), a transcription factor that is central 
to the regulation of many genes, such as those encoding adhesion molecules and angiogenic 
mediators (Grilli et al., 1993). Some natural compounds interfered with NF-κB activation 
and expression of downstream genes in vitro either by blocking NF-κB nuclear translocation 
as we showed with SH-11052, a synthetic isomer of cremastranone (5) (Basavarajappa et al., 
2014), or as seen with withaferin A (14) by targeting the ubiquitin proteasome pathway 
(UPP) which regulates NF-κB activation (Figure 2) (Palombella et al., 1994).
Endothelial cells respond to oxygen, too. Under normal conditions, the oxygen sensor prolyl 
hydroxylase domain protein (PHD) hydroxylates hypoxia-inducible factor 1α (HIF-1α), 
which is then targeted for proteasomal degradation. During hypoxia, PHD is inactivated and 
HIF-1α activates the transcription of multiple genes including growth factors such as VEGF 
and TNF-α, cytokines such as interleukins (IL-6 and IL-8), proinflammatory enzymes such 
as cyclooxygenase 2 (COX2), and proteases such as MMPs. This broad transcriptional 
response increases blood flow and oxygen supply by angiogenesis (Fraisl et al., 2009). 
However, HIF-1α can be activated under non-hypoxic conditions by growth factors such as 
VEGF, causing a vicious cycle of uncontrolled neovascularization. Apigenin (2) interfered 
with HIF-1α signaling in vitro, by initiating HIF-1α degradation and inhibiting the 
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expression of downstream VEGF in HUVECs (Zou and Chiou, 2006). Meanwhile, genistein 
(3) inhibited hypoxia-induced expression of HIF-1α, and deguelin (8) reduced HIF-1α 
expression and mediated its degradation in vivo in the OIR model (Figure 2) (Kim et al., 
2008c; Wang et al., 2005).
A clear characterization of the molecular targets by which the above natural products 
interfere with angiogenesis is still needed. However, unlike most natural products discussed 
here, a direct target of withaferin A (14) is known. It binds to the intermediate filament (IF) 
protein vimentin, which plays a critical role in angiogenesis and cancer growth, causing IF 
degradation and down-regulation of their expression levels. This leads to attenuation of 
retinal gliosis associated with several degenerative conditions in the eye including AMD 
(Bargagna-Mohan et al., 2007; Bargagna-Mohan et al., 2010). Further elucidation of the 
direct targets of other natural compounds is important to develop more specific and potent 
analogs with minimal side effects and to test the combination of different compounds 
targeting distinct angiogenic mechanisms.
7. What does the future hold?
There is considerable promise amongst the natural compounds that are currently under 
investigation specifically for ocular neovascular diseases (Table 1). Almost all compounds 
discussed here were effective in inhibiting in vitro angiogenesis. Withaferin A (14) showed 
high potency in inhibiting angiogenesis in HUVECs. Interestingly, SH-11037, a synthetic 
derivative of cremastranone (5), demonstrated the highest potency among the compounds 
discussed in inhibiting proliferation, migration and tube formation of HRECs, a tissue 
specific and disease relevant cell type. We saw this effect at nanomolar concentrations, 
suggesting a strong potential of SH-11037 in angiogenesis inhibition that is awaiting a clear 
understanding of its mechanism of action and demonstration of its therapeutic potential in 
animal models of ocular neovascular diseases. Intravitreally injected deguelin (8) was very 
potent in suppressing retinal and choroidal neovascularization in vivo in the OIR and laser-
induced CNV models, respectively. However, some undesirable cell toxicity, over a certain 
dose, could be an obstacle for its clinical use (Kim et al., 2008d). Synthetic derivatives of 
deguelin have been studied as an alternative to maintain its therapeutic potential with fewer 
side effects (Kim et al., 2008d). A novel candidate, SH-14, demonstrated high apoptotic 
activity and less cytotoxicity than deguelin on several cancer cell lines, suggesting a better 
potential for cancer prevention and therapy (Kim et al., 2008d). Further studies are needed to 
demonstrate the anti-angiogenic effects of this or other derivatives on ocular neovascular 
diseases.
The pleiotropic effects of curcumin (9) make it an interesting natural product in the ocular 
context. It caused the induction of apoptosis and G0/G1 cell cycle arrest in HUVECs (Singh 
et al., 1996), interfered with VEGF-induced signaling in HRECs (Premanand et al., 2006) 
and blocked FGF-2- signaling in the corneal pocket assay (Mohan et al., 2000). Synthesis of 
curcumin derivatives to target ocular angiogenesis specifically, as well as improve 
bioavailability while minimizing effects on other tissues/pathways might be a reasonable 
approach to develop an effective drug for ocular neovascularization.
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Withaferin A (14) interfered with the UPP in HUVECs and choroidal endothelial cells 
(CECs), suggesting a conserved mechanism of action among different endothelial cell types 
(Bargagna-Mohan et al., 2006). Testing withaferin A activity in ocular disease-relevant 
animal models is required to demonstrate its therapeutic potential in ocular neovascular 
diseases such as ROP, AMD and DR. Importantly, with a direct target of withaferin A 
known (the IF protein vimentin), development of more specific or potent analogs is a 
possibility. Meanwhile, a clear and comprehensive understanding of the mechanism of 
action of other natural compounds in vitro is still needed. This should be done using tissue 
specific endothelial cells and disease-relevant animal models as discussed, which will assist 
in the synthesis of novel analogues to specifically target ocular neovascularization with 
minimal systemic effects.
Other natural compounds, not discussed here, have been tested in a more limited fashion on 
ocular neovascularization, such as astaxanthin (Izumi-Nagai et al., 2008), baicalin (Yang et 
al., 2014), and the fumagillin derivative lodamin (Benny et al., 2010), but still may prove 
promising. Any of these compounds could potentially be effective on their own or after 
medicinal chemistry optimization to increase specificity and potency and improve 
pharmacokinetics. Topical, intravitreal, and systemic administration could achieve drug 
delivery to the ocular tissues. However, drug delivery remains a challenge that depends on 
the physicochemical properties of the compound, physiological barriers and ocular 
permeability. The topical route is the most favored, but the drug formulation and ocular 
permeability may limit the drug bioavailability following this route. Physiological barriers 
such as the blood-retinal barrier and potential undesirable systemic exposure to the drug 
challenge systemic administration as an option for drug delivery to ocular tissues. An 
intravitreal route is invasive by nature but is very effective, therefore the most commonly 
used for experimental studies (Matsumoto et al., 2006; Srirangam et al., 2012; Zhang et al., 
2009), and is of course the delivery route used for existing biologic therapies in the clinic.
The therapeutic use of these natural compounds as inhibitors of ocular angiogenesis is 
awaiting further studies to clearly elucidate their molecular targets and to thoroughly test 
them in disease-relevant animal models before they can proceed towards clinical trials. 
Better understanding of known angiogenic mechanisms and identification of novel pathways 
to interfere with angiogenesis is important for future therapeutic development of more 
effective angiogenesis inhibitors. This strategy could be achieved by further synthesizing 
derivatives that selectively target a specific molecular pathway and/or use of combination 
therapies to target multiple pathways in this complicated pathological process, which could 
offer better therapeutic outcomes for patients afflicted by blinding neovascular eye diseases.
8. Conclusion
Medicinal plants continue to provide new sources of compounds for the treatment of 
disease. Natural products that have been shown to reduce angiogenesis provide an appealing 
alternative to the available biologic pharmacotherapies for ocular neovascular diseases, and 
hopefully more of these compounds will be tested in the ocular context, drawing on the 
wealth of compounds that show antiangiogenic activity in cancer models (Sagar et al., 
2006a, b). Successful compounds could be used alone or in combination treatment with 
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standard therapies to reduce the effective dosage and thereby significantly decrease side 
effects. In order to develop specific anti-angiogenic natural compounds for ocular disease, 
extensive testing still needs to be done.
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Highlights
• Small molecule inhibitors of pathological ocular angiogenesis would be an 
appealing addition to the available biologic therapies
• A growing subset of natural-source compounds are promising suppressors of 
ocular neovascularization in vitro and in vivo
• With further mechanistic studies, some of these compounds would be ready to 
progress toward clinical trials
Sulaiman et al. Page 18
Exp Eye Res. Author manuscript; available in PMC 2015 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1. 
Chemical structures of anti-angiogenic natural products tested in the context of ocular 
neovascular diseases.
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Fig. 2. 
The known locations of natural products' effects on selected angiogenic pathways. 
Angiogenic factors act on their receptors (red) on endothelial cells to activate various 
downstream signaling molecules (green) and transcription factors (yellow) to mediate 
angiogenesis. Several natural products interfere with these angiogenic pathways as indicated 
in purple.
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Table 1
Summary of the potential effects of promising natural compounds in inhibiting ocular angiogenesis in vitro 
and in vivo.
Compound Source In vitro system and effects In vivo models tested
Luteolin (1) Fruits and 
vegetables 
(Miean and 
Mohamed, 
2001)
HUVECs, 5 µM, inhibited VEGF-induced 
VEGFR2 autophosphorylation and 
activation of PI3K/Akt but not ERK1/2 
(Bagli et al., 2004) HRECs, 1 µM, decreased 
VEGF-induced migration and tube 
formation (Park et al., 2012)
• Suppressed VEGF-induced 
angiogenesis in rabbit corneal 
pocket assay (Bagli et al., 2004)
• Intravitreal injection, 0.1 µM on 
P14, suppressed retinal 
neovascularization in OIR mouse 
model (Park et al., 2012)
Apigenin (2) Fruits and 
vegetables 
(Horinaka et al., 
2006)
HUVECs and choroidal endothelial cells 
(CECs), 3 & 10 µg/mL: inhibited 
proliferation, migration and tube formation 
(Zou and Chiou, 2006)
Daily i.p. injection for 4 weeks, 15 and 30 
mg/kg, reduced CNV after laser 
photocoagulation in rats (Zou and Chiou, 2006)
Genistein (3) Soybeans 
(Fotsis et al., 
1993)
BAECs, 20 µM, inhibited migration and 
proliferation due to non-specific inhibition 
of tyrosine kinases (Koroma and de Juan, 
1994)
• Gavage administration, 32 mg/kg, 
had partial inhibitory effects on 
laser-induced CNV mouse model 
compared to specific inhibitors of 
VEGF/PEDF receptor kinases 
(Kwak et al., 2000)
• i.p. injection, 50-200 mg/kg/day 
from P14 to P20, inhibited 
hypoxia-induced expression of 
VEGF and HIF-1α in OIR mouse 
model (Wang et al., 2005)
• Long-term oral dosing, 150 and 
300 mg/kg, decreased vascular 
leakage in STZ rat model of DR 
(Nakajima et al., 2001)
Hesperetin (4) Citrus fruits 
(Kawaii et al., 
1999)
HRECs, 16 µM, inhibited proliferation 
(Basavarajappa et al., 2013)
Long-term oral dosing, 100 mg/kg, in STZ 
rats:
• Significantly improved retinal 
antioxidant defense system
• Decreased retinal levels of 
VEGF, IL-1β and TNFα (Kumar 
et al., 2013)
Cremastranone (5) Cremastra 
appendiculata 
(Shim et al., 
2004)
HUVECs, 5 µM:
• Inhibited FGF-induced 
migration and tube formation
• Suppressed proliferation without 
affecting cell viability by 
causing G2/M phase cell cycle 
arrest (Kim et al., 2007) HRECs, 
GI50 217 nM, inhibited 
proliferation, migration, and 
tube formation (Lee et al., 2014)
• Inhibited capillary formation in 
chick chorioallantoic membrane 
(CAM) assay in a dose-
dependent manner (Shim et al., 
2004)
• Intravitreal, 1 µM on P14, 
reduced neovascularization in 
OIR model without cytotoxic 
effects (Kim et al., 2007)
• Intravitreal, 1 µM, reduced 
vascular leakage in laser-
induced CNV mouse model 
(Kim et al., 2008a)
SH-11052 Synthetic 
isomer of 
cremastranone
HUVECs, GI50 18 µM, inhibited 
proliferation (Basavarajappa et al., 2014)
HRECs, GI50 43 µM,
• Inhibition of proliferation, 
migration, tube formation and 
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Compound Source In vitro system and effects In vivo models tested
cell cycle progression without 
inducing apoptosis
• Decreased TNFα induced NF-
κB activation and the expression 
of downstream genes 
(Basavarajappa et al., 2014)
SH-11037 Synthetic 
derivative of 
cremastranone
HRECs, GI50 150 nM, very potent in 
inhibiting proliferation with 10-fold 
selectivity over HUVECs (Basavarajappa et 
al., 2014)
Quercetin (6) Abundant in 
human food – 
e.g. apples and 
onions (Formica 
and Regelson, 
1995)
• Inhibited proliferation, migration 
and tube formation of the 
Rhesus choroidretina endothelial 
cell line (RF/6A) (Chen et al., 
2008)
• BAECs, GI50 20 µM, inhibition 
of proliferation by a dual 
mechanism; suppression of 
endothelial nitric oxide synthase 
(eNOS) and early M phase cell 
cycle arrest (Jackson and 
Venema, 2006)
• Inhibited oxidation-induced 
damage in HUVECs (Zhuang et 
al., 2011)
• 1% quercetin eye drops, 3 drops/
day, inhibited laser-induced 
CNV formation in rats (Zhuang 
et al., 2011)
Isoliquiritigenin (7) Licorice root 
(Vaya et al., 
1997)
HUVECs:
• Suppressed cell growth in both 
VEGF-dependent and 
independent fashion at a 
subtoxic concentration of 10 µM 
(Cao et al., 2010)
• Inhibited migration and tube 
formation in a dose- and time-
dependent manner (Kang et al., 
2010)
• Downregulated VEGF and 
upregulated PEDF expression 
levels (Jhanji et al., 2011)
• Significantly reduced 
vasculature formation in a CAM 
assay (Jhanji et al., 2011)
• Intravitreal injection, 10–200 
µM, dosedependent decrease in 
vascular leakage and 
neovascular area in the laser-
induced CNV mouse model 
(Jhanji et al., 2011)
• Intravitreal, 10 but not 100 µM 
on P12, significant reduction in 
retinal neovascularization in the 
OIR model (Jhanji et al., 2011)
Deguelin (8) Mundulea 
sericea 
(Gerhauser et 
al., 1997)
HUVECs, 0.1 µM, inhibited tube formation 
without affecting cell viability and 
dramatically reduced VEGF expression 
(Kim et al., 2008b)
• Blocked angiogenesis in the 
CAM assay (Kim et al., 2008b)
• Intravitreal, 0.1 µM, 
significantly reduced CNV and 
leakage in mice after laser 
photocoagulation (Kim et al., 
2008b)
• Intravitreal, 0.1 µM on P14, 
reduced retinal 
neovasculariozation in the OIR 
mouse model (Kim et al., 2008c)
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Compound Source In vitro system and effects In vivo models tested
Curcumin (9) Indian spice 
turmeric 
(Kuttan et al., 
1987)
• HUVECs, decreased 
proliferation and induced 
apoptosis through the induction 
of G0/G1 cell cycle arrest (Singh 
et al., 1996)
• HRECs, 10 µM, inhibited 
proliferation (Premanand et al., 
2006)
• Interfered with FGF-2 signaling 
in the corneal pocket assay 
(Mohan et al., 2000)
• Dietary, 0.5 g/kg, inhibited 
diabetes-induced retinal 
oxidative stress and production 
of pro-inflammatory mediators 
in the STZ rat model (Kowluru 
and Kanwar, 2007)
Resveratrol (10) Red wine and 
grape skin 
(Soleas et al., 
1997)
• HUVECs, 1–2.5 µM, blocked 
VEGF-induced migration and 
tube formation (Lin et al., 2003)
• After hyperoxic injury of 
primary cultured retinal cells, 
resveratrol reduced eNOS 
expression by modulating NO-
mediated mechanisms (Kim and 
Suh, 2010)
• Suppressed the formation of new 
vasculature in the CAM assay 
(Brakenhielm et al., 2001)
• Inhibited VEGF- and FGF-2-
induced neovascularization in 
the mouse corneal pocket assay 
(Brakenhielm et al., 2001)
• Dietary, 5 mg/kg/day, inhibited 
NK-κB activation and apoptosis 
in retinas of STZ rats (Soufi et 
al., 2012)
• i.p. injection, 30 mg/kg daily 
from P14 to P20, reduced eNOS 
expression by modulating NO-
mediated mechanisms in OIR rat 
model (Kim and Suh, 2010)
Honokiol (11) Magnolia 
species (Lee et 
al., 2011)
• Inhibited proliferation of 
HUVECs, but not primary 
fibroblasts, through suppressing 
VEGFR2 autophosphorylation 
(Bai et al., 2003)
• Suppressed reactive oxygen 
species production, NF-κB 
activation and expression of 
COX2 in high glucosestimulated 
HUVECs (Sheu et al., 2008)
• i.p. injection, 10–20 mg/kg daily 
from P12 to P17, inhibited 
pathological retinal angiogenesis 
and promoted physiological 
revascularization in the OIR 
model (Vavilala et al., 2013)
Combretastatin A4 (12) Combretum 
caffrum (Young 
and Chaplin, 
2004)
HUVECs, 80 ng/ml, inhibited proliferation, 
migration and tube formation, with induction 
of apoptosis after 48 hours (Ahmed et al., 
2003)
• i.p. injections, 0.78–12 mg/kg 
daily from P13 to P17, dose-
dependently inhibited retinal 
neovascularization in the OIR 
mouse model (Griggs et al., 
2002)
• Intravenous injection failed to 
ameliorate retinal 
neovascularization induced by 
longterm galactose feeding in 
dogs (Kador et al., 2007)
• i.p. injection, 4 mg/kg, inhibited 
VEGF-induced retinal 
neovascularization in transgenic 
mice overexpressing VEGF in 
retina (rho/VEGF) (Nambu et 
al., 2003)
• i.p. injections daily for one 
week, 100 mg/kg, significantly 
reduced CNV after laser 
photocoagulation in mice 
(Nambu et al., 2003)
Decursin (13) Angelica gigas 
(Konoshima et 
al., 1968)
• HUVECs, 2–20 µM, 
significantly inhibited VEGF-
mediated proliferation,migration 
• Reduced neovascularization in 
the CAM assay and Matrigel 
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Compound Source In vitro system and effects In vivo models tested
and tube formation in a 
dosedependent manner (Jung et 
al., 2009)
• HRECs, 12.5–100 µM, inhibited 
proliferation, migration and tube 
formation by effectively down-
regulating VEGFR2 expression 
and blocking its phosphorylation 
(Yang et al., 2013)
plug assay in mice (Jung et al., 
2009)
• Orally, supplemented in drinking 
water at 20 mg/kg/day, 
suppressed VEGFR2 expression 
levels in the STZ rat model 
(Yang et al., 2013)
• Intravitreal, 5 µM on P14, 
reduced retinal 
neovascularization in the OIR 
model (Kim et al., 2009)
Withaferin A (14) Withania 
somnifera 
(Mohan et al., 
2004)
• HUVECs, GI50 12 nM: 
decreased proliferation and 
induced apoptosis by causing a 
dose-dependent decrease in 
cyclin D1 expression levels and 
inhibited NF-κB signaling at 
lower concentrations (Fugner, 
1973; Mohan et al., 2004)
• CECs, inhibited TNFα-induced 
angiogenesis (Bargagna-Mohan 
et al., 2006)
• i.p. injection, anti-angiogenic 
activity in the FGF-2 Matrigel 
plug mouse model; at 500-fold 
lower doses that those reported 
for its anti-tumor activity in vivo 
(Mohan et al., 2004)
• i.p. injection, 2 mg/kg, inhibited 
corneal neovascularization and 
retinal gliosis elicited by alkali 
injury with corneal scraping in 
mouse eye (Paranthan et al., 
2011)
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